Dr. Martens (LON:DOCS) Issues Quarterly Earnings Results

Dr. Martens (LON:DOCS) released its earnings results on Thursday. The company reported GBX (1) earnings per share for the quarter, Digital Look Earnings reports. The business had revenue of £290.40 million for the quarter. Dr. Martens had a return on equity of 6.89% and a net margin of 3.11%.

Here are the key takeaways from Dr. Martens’ conference call:

• Revenue fell 9.2% year over year to £292.4 million, and adjusted EBIT swung to a £2.2 million loss from a £3.1 million profit. The decline was concentrated in Europe and DTC, with boots sales down 20% amid unusually hot weather and ongoing pressure on core styles.
• Margin and cost discipline cushioned the sales decline: gross margin rose 80 basis points on a comparable basis to 65.4%, while operating costs benefited from prior cost actions. Management said margin should remain resilient, though some first-half benefits may ease in the second half.
• Debt remained broadly flat year over year at £158.9 million, and covenant net debt to EBITDA was 2.2 times versus a 3.0-times limit. Cash generation was seasonally negative by £66.2 million as the company built working capital ahead of peak trading.
• The company reported encouraging early responses to its With Bouncing Soles campaign, upgraded Brand Centres, and new Spring/Summer sandals range. Management cautioned that the campaign and store results are still early, and the new e-commerce platform has required time to bed in.
• Second-half performance is pivotal: management expects boots to remain a headwind for the rest of FY 2027, with core boot styles still under pressure, and said the business is focused on the key trading weeks ahead. Its full-price mix priorities in the U.K. and DACH are weighted to the second half.

Dr. Martens Stock Down 4.8%

Shares of DOCS opened at GBX 51.50 on Friday. Dr. Martens has a 52 week low of GBX 51 and a 52 week high of GBX 90. The stock has a market capitalization of £492.99 million, a price-to-earnings ratio of 21.46, a PEG ratio of 6.40 and a beta of 0.26. The company has a debt-to-equity ratio of 108.85, a quick ratio of 1.13 and a current ratio of 2.61. The stock has a fifty day moving average of GBX 66.75 and a 200-day moving average of GBX 69.42.

Insider Buying and Selling at Dr. Martens

In related news, insider Ije Nwokori sold 209,160 shares of the business’s stock in a transaction on Friday, October 16th. The stock was sold at an average price of GBX 69, for a total transaction of £144,320.40. Over the last 90 days, insiders acquired 927 shares of company stock worth $59,965. Company insiders own 2.97% of the company’s stock.

Top Dr. Martens Stories

Here are a few of the latest stories about DOCS:

• Negative Sentiment: Trading concerns are the main drag: first-half revenue fell 9%, while boot sales dropped 20%, with a hot summer cited as a factor. Management warned that the coming trading season is crucial, raising the stakes for holiday-period demand. Half-year revenue and trading outlook Boot sales report
• Negative Sentiment: Peel Hunt cut its rating from “Buy” to “Add” amid the concerns. Coverage also described the shares’ decline as their largest daily fall in six months, reflecting the market’s reaction to the sales update and outlook. Peel Hunt rating change Share decline report
• Negative Sentiment: Quarterly results included EPS of negative 1 GBX and revenue of £290.4 million, adding to investor concern about near-term performance. Quarterly results

Analysts Set New Price Targets

Separately, Berenberg Bank reaffirmed a “buy” rating and issued a GBX 110 price objective on shares of Dr. Martens in a research note on Friday, October 9th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of GBX 105.

About Dr. Martens

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot – named after the date it was produced – rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, “Docs” or “DM’s” were later adopted by musicians and subcultural pioneers who took them from the street to the global stage. Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.